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The prevalence of diabetes is increasing, and patients with diabetes are at increased risk of
adverse cardiovascular outcomes. Recently, the results from 11 large randomized clinical trials
have suggested a difference in the emergence of new diabetes according to cardiovascular
medication use. Treatment with angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, and calcium antagonists yielded a lower incidence of diabetes development
than beta-blockers and diuretics. Physicians should consider this possible diabetes conse-
quence when prescribing long-term beta-blockers and diuretics, particularly in patients at
high risk of developing diabetes. (J Am Coll Cardiol 2004;44:509–12) © 2004 by the
American College of Cardiology Foundationc
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che epidemic of diabetes in the U.S. and elsewhere has
een well publicized and has devastating implications on
uture cardiovascular (CV) disease and its adverse outcomes.
atients with diabetes have a two- to four-fold increase in
V mortality (1), and diabetes is the leading cause of
nd-stage renal disease (2). Recently, major emphasis has
een placed on educating the public regarding the hazards
f inactivity and obesity, which require long-term patient
ehavior modification to alter and which are major risk
actors for diabetes development. However, much less at-
ention has been given to physician practice patterns relative
o drug prescribing, particularly in patients at high risk of
eveloping diabetes.
Because CV disease, particularly coronary artery disease
CAD), and its risk conditions are life long, patients will
equire use of CV medications for many years. This pro-
onged medication exposure has led to questions regarding
he potential of certain drugs to protect against or hasten
iabetes development, although they are useful for the
anagement of CAD and associated co-morbidities like
ypertension (3–5). To this end, pharmacologic and epide-
iologic studies have documented that certain drugs, pri-
arily thiazide diuretics and beta-blockers (BBs), frequently
sed in patients with CAD or at high risk of CAD, are
ssociated with metabolic disturbances that may result in
ncreased insulin resistance (6 –9). However, other
ngiotensin-active agents, primarily angiotensin-converting
nzyme (ACE) inhibitors and angiotensin receptor blockers
ARBs), appear to improve insulin sensitivity and glucose
etabolism (6). Calcium antagonists (CAs), on the other
and, appear to be neutral with regard to metabolic effects
10–12).
Since 1999, there have been 11 prospective, randomized
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lorida.
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igh risk of CV disease treated with standard CV therapies
or prevention management (13–23). Included among these
re a total of 14,590 black and 13,391 Hispanic patients,
nd 94% of all patients had a mean age of 60 years at the
ime of enrollment. Data from these trials add to the
rowing evidence that supports the notion that certain CV
rugs have important effects on diabetes development, and
he strength of this evidence is now too strong for physicians
o ignore. These trials include over 88,000 patients who did
ot have diabetes at enrollment. After follow-up, ranging
rom one to eight years, there are consistent findings related
o classes of drug treatment and the development of new
iabetes. The purpose of this paper is to examine this
vidence base, which is summarized in Figure 1.
The initial report of a difference in new diabetes emer-
ence in a large randomized CV disease trial came from the
aptopril Prevention Project (CAPPP) (13), where 10,413
ypertensive, nondiabetic patients were randomized to ei-
her a captopril or BB with or without thiazide diuretic
reatment group. After a mean follow-up of 6.1 years,
.5% of those assigned to captopril versus 7.3% of those
ssigned to BB/thiazide diuretic developed diabetes. A short
ime later, the Swedish Trial in Old Patients with
ypertension-2 (STOP-2) study investigators (14) reported
n 5,895 nondiabetic, hypertensive elderly patients, a non-
ignificant trend in the development of new diabetes by
omparing treatment groups containing either BBs and/or
iuretics (atenolol, metoprolol, pindolol, or hydrochlorothi-
zide [HCTZ] plus amiloride) (4.9%), an ACE inhibitor
either enalapril or lisinopril) (4.7%), or a CA (either
elodipine or isradipine) (4.8%).
The Heart Outcomes Prevention Evaluation (HOPE)
hen reported on 5,720 nondiabetic patients with or at high
isk of CAD, randomized to ramipril or placebo plus usual
are medications (15). Usual care included CAs, BBs,
nd/or diuretics in most cases. After 4.5 years, 3.6% of those
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CV Therapies and Diabetes Risk August 4, 2004:509–12ssigned to ramipril and 5.4% of those assigned to placebo
eveloped new diabetes. Recently, the HOPE investigators
eported results from HOPE-TOO, which extends
ollow-up to 7.1 years in a subset of 6,786 patients. Despite
he majority (67%) of HOPE-TOO patients being contin-
ed on or switched to ramipril during the additional 2.6
ears of follow-up, of those who were nondiabetic at HOPE
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ARB  angiotensin receptor blocker
BB  beta-blocker
CA  calcium antagonist
CAD  coronary artery disease
CV  cardiovascular
HCTZ  hydrochlorothiazide
HOPE  Heart Outcomes Prevention Evaluation
SCOPE  Study on Cognition and Prognosis in the
Elderly
STOP-2  Swedish Trial in Old Patients with
Hypertension-2
igure 1. Incidence of new diabetes according to study and drug treatme
onfidence interval (CI), as published. †Mean years of follow-up. ‡With
nd 95% CI were estimated from data provided in publication, using the
lood sugar at year 4 (C, n  2,606; A, n  1,567; L, n  1,464). ¶
ngiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor block
andomized open blinded end point. CAPPP  Captopril Prevention Proj
osartan Intervention For Endpoint reduction; ALLHAT  Antihyperte
econd Australian National Blood Pressure Study; ALPINE  Antihyper
HARM  Candesartan in Heart failure Assessment of Reduction in Mortalityntry and continued to be followed, 7.2% and 10.2% of
hose originally assigned to ramipril and placebo, respec-
ively, developed diabetes.
Next, the Intervention as a Goal in Hypertension Treat-
ent (INSIGHT) investigators reported on 5,019 nondia-
etic, hypertensive patients randomized to either the nifed-
pine gastrointestinal transport system (GITS) or thiazide
iuretic co-amilozide with or without a BB (16). After
lmost five years, 5.4% of those assigned to nifedipine GITS
nd 7.0% of those assigned the thiazide diuretic developed
ew diabetes. The Losartan Intervention Evaluation
LIFE) group then reported that among 7,998 nondiabetic,
ypertensive patients with left ventricular hypertrophy, new
iabetes occurred in 6% of those assigned to losartan and 8%
n those assigned to atenolol with or without HCTZ (17).
hortly thereafter, the Antihypertensive and Lipid-
owering Treatment to Prevent Heart Attack Trial (ALL-
AT) investigators reported that among 21,294 nondia-
etic patients with hypertension, 9.8% of those assigned to
mlodipine, 8.1% assigned to lisinopril, and 11.6% assigned
o chlorthalidone developed diabetes (18).
he risk ratio presented is either the relative risk or hazard ratio and 95%
ithout background beta-blockers (BBs) and diuretics. §The relative risk
el-Haenszel method. Reported as the percentage of patients with fasting
follow-up for each patient. Solid bars  BBs/diuretics; open bars 
RB)/calcium antagonist (CA). DB double blind; PROBE prospective
NSIGHT  Intervention as a Goal in Hypertension Treatment; LIFE 
and Lipid-Lowering treatment to prevent Heart Attack Trial; ANBP2 
e Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation;nt. *T
or w
Mant
Total
er (A
ect; I
nsive
tensivand Morbidity; INVEST  International Verapamil-Trandolapril Study.
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August 4, 2004:509–12 CV Therapies and Diabetes RiskThe Second Australian National Blood Pressure Study
ANBP2) revealed that among 5,626 nondiabetics, 4.54% of
hose treated with enalapril compared with 6.58% of those
reated with HCTZ developed diabetes (19). Soon there-
fter, the Study on Cognition and Prognosis in the Elderly
SCOPE) investigators reported that of the 4,342 nondia-
etics enrolled, 4.3% of those treated with candesartan
ompared with 5.3% of the those treated with placebo (and
ackground antihypertensives) developed diabetes (20).
hen, the Antihypertensive Treatment and Lipid Profile in
North of Sweden Efficacy Evaluation (ALPINE) trialists
eported on 392 nondiabetic, low-risk Scandinavian hyper-
ensive patients (21). They found new diabetes in only 0.5%
f those assigned to candesartan with or without felodipine
nd 4.0% of those assigned to HCTZ with or without
tenolol.
The Candesartan in Heart Failure Assessment of Reduc-
ion in Mortality and Morbidity (CHARM) investigators
ubsequently reported that among 5,439 nondiabetic
hronic heart failure patients, 6.0% of those assigned to
andesartan and 7.4% of those assigned to placebo added to
background of BBs and diuretics in most cases, developed
iabetes (22). Finally, the International Verapamil-
randolapril Study (INVEST) trialists reported that in
6,176 nondiabetic, hypertensive patients with CAD, the
ncidence of new diabetes was significantly lower in the
erapamil sustained release/trandolapril strategy (7%), com-
ared with the atenolol/HCTZ strategy (8.2%) (23). Treat-
ent with HCTZ was associated with new diabetes in both
trategies, whereas increased exposure to the ACE inhibitor
randolapril in the verapamil sustained release strategy
ppeared to be associated with more protection from new
iabetes than the atenolol/HCTZ strategy.
These data from 11 trials appear consistent. In each of
hese trials, the point estimate for risk of new diabetes
igure 2. Percent reduction of new diabetes in randomized clinical trials
ategorized by treatment groups containing predominantly either an ACE
nhibitor or ARB (open bars), CA plus either an ACE inhibitor or ARB
striped bars), or CA alone (solid bars). The comparator groups contained
redominantly either BBs and/or thiazide diuretics. Abbreviations as in
igure 1.uggested fewer cases in one randomly assigned treatment troup than the other, and in nine of these 11 trials, the
ifference was statistically significant. The percent reduction
n new diabetes according to the type of treatment medica-
ion is displayed in Figure 2. There were many common
ndings comparing the studies. All were prospective, ran-
omized, and included patients with or at high risk of
AD, and the majority had less than optimal blood pres-
ure. Most compelling is that the treatment groups contain-
ng either agents blocking the effects of angiotensin II
ACE inhibitors or ARBs) and/or CAs had fewer patients
ho developed diabetes than treatment groups containing
iuretics and/or BBs.
As expected, there are some limitations to these trials.
mportant among these are that only 7 of the 11 trials were
ouble-blind, whereas the other 4 (13,14,19,23) utilized the
rospective randomized open blinded end point (PROBE)
esign (24). In some of these trials, thiazide diuretics and/or
Bs were used in some patients assigned to agents blocking
he effects of angiotensin II (ACE inhibitors or ARBs)
13,15–20,22,23) or CAs. This design probably minimized
he differences observed in emergence of new diabetes
etween the treatment groups in these trials. The definition
f “diabetes” differed among the trials. The same or similar
lood pressure reduction was not achieved in each of the
reatment groups in all of the studies, which may have
ontributed to the disproportionate development of diabetes
etween treatment groups in some of the studies (17,18,20).
astly, STOP-2 and SCOPE (14,20), which demonstrated
non-significant trend, enrolled elderly subjects (at least 70
ears old; mean age 76 years). Data from Narayan et al. (25)
uggest a plateau in the cumulative development of diabetes
y 80 years of age, which many of these patients would have
xceeded by the end of five to six years of follow-up.
dditionally, the STOP-2 and SCOPE patients were all
aucasian and relatively lean (mean body mass index 27
g/m2) and did not have significant CV or other co-
orbidities, so they were at the lowest risk of developing
iabetes (20,25,26). Furthermore, in the STOP-2 study, the
oses of antihypertensive agents in each of the three
reatment groups were relatively low in comparison to the
rials subsequently published, which may have contributed
o the non-significant differences in new diabetes when
omparing the groups. These limitations notwithstanding,
e believe that the total data set is very compelling, but
learly more research needs to be done in this important
rea.
These data suggesting a significant reduction in the risk
f new diabetes, ranging from 15% to 87%, resulting from
rug therapies containing ACE inhibitor, ARB, or CA
gents, should not be ignored. In addition, recent data
uggesting there are patient characteristics that may be
ssociated with an increase in the risk of new diabetes (i.e.,
hronic heart failure, left ventricular hypertrophy, U.S.
esidency, Hispanic ethnicity, black race, previous stroke,
ncreased body mass index, low serum high-density lipopro-
ein, high non-fasting serum glucose, elevated systolic blood
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CV Therapies and Diabetes Risk August 4, 2004:509–12ressure, increased age, female gender, and history of
ntihypertensive drug use) (25,27,28) make it imperative for
hysicians to take notice of these factors when selecting
ong-term CV medications for patients, particularly those at
igh risk of developing diabetes. Once patients develop
iabetes, the CV risk implications are significant, and after
mean of six years, patients who develop diabetes after
ntihypertensive medication use are at the same increased
isk of CV adverse outcomes as established diabetics (29).
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